Novartis (NOVN SW) - Q2 2026 (USD): Net Revenue 14.4bln (exp. 14.1bln), Core EPS 2.41 (exp. 2.20), Operating income 4.75bln (prev. 4.86bln Y/Y), Net income 3.26bln (prev. 4.02bln Y/Y), backs FY26 view

Sales (USD): Entresto 1.18bln (exp. 1.29bln) Cosentyx 1.82bln (exp. 1.14bln) FY outlook: Expects net sales to grow low single-digit. Expects core operating income to decline low single-digit. CEO: “Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto." "We are on track for multiple  important readouts ahead in the second half, and remain on track to deliver our full-year guidance and mid-term outlook.”